Drug Information

Drug General Information
Drug ID
D06DMQ
Former ID
DIB000443
Drug Name
VX-970
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 1 [532880], [532980]
Company
Vertex pharmaceuticals
Structure
Download
2D MOL

3D MOL
Target and Pathway
Target(s) Serine threonine protein kinase ATR Target Info Inhibitor [532880], [532980]
KEGG Pathway Fanconi anemia pathway
Cell cycle
p53 signaling pathway
HTLV-I infection
PANTHER Pathway p53 pathway
p53 pathway feedback loops 2
Pathway Interaction Database Fanconi anemia pathway
ATR signaling pathway
Signaling events mediated by TCPTP
Circadian rhythm pathway
BARD1 signaling events
p53 pathway
Reactome Meiotic synapsis
Activation of ATR in response to replication stress
Regulation of HSF1-mediated heat shock response
HDR through Single Strand Annealing (SSA)
Processing of DNA double-strand break ends
Presynaptic phase of homologous DNA pairing and strand exchange
G2/M DNA damage checkpoint
WikiPathways DNA Damage Response
Meiotic Synapsis
Prostate Cancer
Integrated Breast Cancer Pathway
Integrated Cancer pathway
Cell Cycle
Cell Cycle Checkpoints
miRNA Regulation of DNA Damage Response
References
Ref 532880Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970. Oncotarget. 2014 Jul 30;5(14):5674-85.
Ref 532980ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer Res. 2014 Dec 1;74(23):6968-79.
Ref 532880Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970. Oncotarget. 2014 Jul 30;5(14):5674-85.
Ref 532980ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer Res. 2014 Dec 1;74(23):6968-79.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.